Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-10-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document details the shareholding status, changes in ownership, and contractual relationships (such as collateral agreements) of major shareholders. In the context of global financial reporting, this falls under the category of 'Major Shareholding Notification' (MRQ), as it tracks significant ownership thresholds and changes in control.
2023-10-06 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses media reports about potential investment and provides updates on the status of a non-binding Letter of Commitment (LOC). Since this is a standard regulatory disclosure regarding market rumors and does not fit into specific categories like M&A or Capital Updates (as it is a clarification of status rather than a definitive transaction announcement), it falls under the general regulatory filing category.
2023-10-06 Korean
해외증권시장주권등상장(종속회사의주요경영사항)
Delisting Announcement Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMax) regarding the listing of its subsidiary (NKGen Biotech, Inc.) on the NASDAQ exchange. It details the number of shares listed, the exchange, the listing date, and the nature of the transaction (a SPAC merger). This falls under general regulatory announcements regarding corporate actions and capital structure changes, fitting the 'Regulatory Filings' (RNS) category as it is a formal disclosure of a material corporate event.
2023-10-04 Korean
주권관련사채권의취득결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (NKMax) detailing the acquisition of convertible notes and warrants in a subsidiary (NKGen Biotech) as part of a SPAC merger and PIPE investment. It contains specific financial terms, board resolution dates, and details on the financial instruments involved. This falls under the category of capital and financing updates as it describes the company's investment and capital structure changes.
2023-09-15 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a private placement of bonds with warrants). It details the issuance amount, payment date, and the nature of the securities. This falls under the category of capital and financing updates, as it reports on the completion of a fundraising activity.
2023-09-13 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a private placement of convertible bonds). It details the issuance amount, payment date, and the nature of the securities. This falls under the category of capital and financing updates as it relates to the company's capital structure and fundraising activities.
2023-09-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.